Matthew BonaparteBashir DweikEmmanuel FeroldiClaude MericAlain BouckenoogheStephen HildrethBranda HuSutee YoksanMark BoazSanofi Pasteur Global Clinical Immunology DepartmentSanofi Pasteur Clinical Development DepartmentSanofi PasteurMahidol University2018-11-092018-11-092014-03-21BMC Infectious Diseases. Vol.14, No.1 (2014)147123342-s2.0-84899091780https://repository.li.mahidol.ac.th/handle/20.500.14594/34262Background: During clinical development of the licensed Japanese encephalitis chimeric virus vaccine (JE-CV), the neutralization capacity of vaccine-induced antibodies was assessed against the vaccine virus and against well characterized wild-type (wt) viruses isolated between 1949-1991. We assessed whether JE-CV-induced antibodies can also neutralize more recent wt Japanese encephalitis virus (JEV) isolates including a genotype 1 isolate.Methods: Sera from 12-18 month-old children who received a single dose of JE-CV in a phase III study in Thailand and the Philippines (ClinicalTrials.gov NCT00735644) were randomly selected and pooled according to neutralization titer against JE-CV into eight samples. Neutralization was assessed by plaque reduction neutralization tests (PRNT50) against three recent isolates from JEV genotypes 1 and 3 in addition to four JEV previously tested.Results: Neutralization titers against the three recent JEV strains were comparable to those observed previously against other strains and the vaccine virus. The observed differences between responses to genotype 1 and 3 viruses were within assay variability for the PRNT50.Conclusions: The results were consistent with previously generated data on the neutralization of wt JEV isolates, immune responses induced by JE-CV neutralize recently isolated virus from southeast (SE) Asia and India. © 2014 Bonaparte et al.; licensee BioMed Central Ltd.Mahidol UniversityMedicineArticleSCOPUS10.1186/1471-2334-14-156